Unipolar Depression Clinical Trial
— SADS-CSOfficial title:
Response to Social Rejection in Suicidal Behavior
Verified date | December 2021 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Suicide is a major health problem that causes annually a million death worldwild. In the stress-vulnerability model, suicidal behavior (SB) results from the interaction between an individual's predisposition and stressful condition. We hypothesized that the sensitivity to social exclusion may represent a core component of the suicidal vulnerability Recent evidence also suggest that inflammatory mediators plays a critical role in SB. Furthermore, social stressors are particulary strong and specific triggers of inflammatory response. To sum up, patients carrying a suicidal vulnerability are expected to present greater responses to social rejection in terms of inflammatory activity and psychological pain. The aim of the study is to evaluate the psychological and inflammatory responses to a social stressor validated, the Trier Social Stress Test (TSST) . We will also investigate the moderating effect of childhood abuse, attachment, trait rejection sensitivity and social isolation. In the second part of the study, we will also investigate the prospective association between inflammatory responses induces by laboratory paradigms of social rejection and the occurrence of social distress, suicidal ideation and psychological pain in response to social exclusion events in real life (using ecological momentary assessment).
Status | Terminated |
Enrollment | 79 |
Est. completion date | February 15, 2018 |
Est. primary completion date | February 15, 2018 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: - Non specifics - Female - Between 18 and 65 years - Main diagnosis of unipolar major depressive episode (DSM-IV criteria) - Having signed informed consent - Able to understand nature, aims, and methodology oh the study - Specifics : - Having a personal history of suicidal behavior (group : depressed patient with history of SB) OR - Not Having personal history of suicidal behavior (group : depressed patient without history of SB) Exclusion criteria: - Inflammatory or intercurrent pathology - Lifetime history of schizophrenia, or schizoaffective or bipolar disorder, according to DSM-IV criteria; - Current diagnosis of substance abuse or dependence in the last year (excluding tobacco) - Current organic mental disorder or mental retardation, or severe comorbid medical condition - Participation in another clinical trial - Pregnancy - Not able to speak, read and understand French - Patient on protective measures (guardianship or trusteeship) |
Country | Name | City | State |
---|---|---|---|
France | University Hospital of Montpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psychological pain response to Trier Social Stress Test (TSST) assessed by visual analogic sale | comparaison of psychological pain response between group with personal history of suicid attempt and group without personal history of suicid attempt | up to one week | |
Secondary | Inflammatory response to TTST | comparaison of blood markers of inflammation between groups | up to one week | |
Secondary | Impact of loneliness and childhood abuse on inflammatory markers | comparaison of sacles scores (ESUL : loneliness scale and CTQ : childhood abuse scale) between groups on inflammatory markers | up to one week | |
Secondary | impact of neuropschychological function on psychological pain | comparaison of neuropsychological tests between groups on psychological pain assessed by visual analogic scale | up to one week | |
Secondary | Social rejection assessed by likert scale in real life condition with a smartphone | comparaison between groups whether inflammatory / psychological pain reactivity to a single experimental episode of social rejection in the laboratory relates to real-world social experience. It consists on self-assessments (with a smartphone) by Likert scales (feelings of social disconnection or rejection during their most recent social interaction, mood, negative affects, suicidal ideation, psychological pain), 5 times per day during 7 days | 7 days after the TSST |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03256162 -
Ketamine as an Adjunctive Therapy for Major Depression
|
Phase 1 | |
Recruiting |
NCT05570110 -
Enoxolone in Major Depression - Biomarker-outcome Relationship
|
Phase 1/Phase 2 | |
Completed |
NCT02530164 -
Transcranial Direct Current Stimulation (tDCS) As Treatment for Major Depression
|
N/A | |
Completed |
NCT00964054 -
Depression Outcomes Study of Exercise
|
Phase 1 | |
Completed |
NCT01447602 -
A Clinical Trial of IPT-A to Prevent Suicide in Depressed Adolescents With Suicidal Behavior
|
Phase 3 | |
Completed |
NCT00517387 -
The Effects of Quetiapine XR on Cognition, Mood and Anxiety Symptoms in SSRI-Resistant Unipolar Depression
|
Phase 3 | |
Recruiting |
NCT04939649 -
Ketamine as an Adjunctive Therapy for Major Depression (2)
|
Phase 3 | |
Recruiting |
NCT05894980 -
How to Reduce Suicidal Thoughts and Impulsivity in Depression
|
N/A | |
Terminated |
NCT04712968 -
Efficacy of Daylight as Adjunctive Treatment in Patients With Depression
|
N/A | |
Enrolling by invitation |
NCT04717921 -
Assesment of Retinal Nerve Fiber Layer in First Episode Depressive Patients Using Selective Serotonin Reuptake Inhibitor
|
||
Recruiting |
NCT03358056 -
Effects of Mindfulness Based Cognitive Therapy on Emotional Processing
|
N/A | |
Recruiting |
NCT03711019 -
Efficacy of Convulsive Therapies During Continuation
|
N/A | |
Completed |
NCT02111915 -
Thinking Healthy Program - Peer Delivered (Pakistan)
|
N/A | |
Completed |
NCT02104232 -
Thinking Healthy Program - Peer Delivered, India (THPP-I)
|
N/A | |
Terminated |
NCT01219686 -
EScitalopram PIndolol ONset of Action
|
Phase 2/Phase 3 | |
Completed |
NCT00158990 -
Triiodothyronine (T3) Supplementation in the Treatment of Bipolar and Unipolar Depression.
|
Phase 3 | |
Completed |
NCT01049347 -
Amitriptyline and Paroxetine Treatment of Major Depression
|
Phase 3 | |
Completed |
NCT03268434 -
Evaluation of Metacognitive Training for Depression (D-MCT) in Outpatient Care
|
N/A | |
Completed |
NCT01880957 -
PET and MRI Brain Imaging of Bipolar Disorder
|
N/A | |
Completed |
NCT04420793 -
Voice Changes During ECT
|